23 October 2025
23 October 2025
The deals will bolster Takeda’s ADC portfolio, which the company now considers a key modality focus within its oncology business.
The acquisition will add Avadel’s FDA-approved Lumryz to Alkermes’ commercial portfolio.
Despite several macroeconomic pressures, biotech venture financing swelled to $3.1bn in Q3 2025.
The transaction will be finalised by the end of the first quarter of 2026.
The partnership includes an upfront payment to Ventus, with potential for additional milestone payments that could surpass $460m.
The latest in a trend of companies stepping back from cell and gene therapies amid regulatory uncertainty and manufacturing challenges.
The acquisition will add Avadel’s FDA-approved Lumryz to Alkermes’ commercial portfolio.
Despite several macroeconomic pressures, biotech venture financing swelled to $3.1bn in Q3 2025.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
